Report Detail
Global Hyperphosphatemia Drugs Market Research Report 2019
- RnM3108304 |
- 12 March, 2019 |
- Global |
- 91 Pages |
- QYResearch |
- Pharma & Healthcare
hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.
The global Hyperphosphatemia Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Hyperphosphatemia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hyperphosphatemia Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Keryx Biopharmaceuticals
Sanofi
Shire
Vifor Pharma
Amgen
Bayer
...
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Aluminum Phosphate Binder
Iron Phosphate Binder
Magnesium Phosphate Binder
Calcium Phosphate Binder
Segment by Application
Hospitals
Clinics
Others
Table of Contents
Executive Summary
1 Hyperphosphatemia Drugs Market Overview
- 1.1 Product Overview and Scope of Hyperphosphatemia Drugs
- 1.2 Hyperphosphatemia Drugs Segment by Type
- 1.2.1 Global Hyperphosphatemia Drugs Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Aluminum Phosphate Binder
- 1.2.3 Iron Phosphate Binder
- 1.2.4 Magnesium Phosphate Binder
- 1.2.5 Calcium Phosphate Binder
- 1.3 Hyperphosphatemia Drugs Segment by Application
- 1.3.1 Hyperphosphatemia Drugs Consumption Comparison by Application (2014-2025)
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Others
- 1.4 Global Hyperphosphatemia Drugs Market by Region
- 1.4.1 Global Hyperphosphatemia Drugs Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Hyperphosphatemia Drugs Market Size
- 1.5.1 Global Hyperphosphatemia Drugs Revenue (2014-2025)
- 1.5.2 Global Hyperphosphatemia Drugs Production (2014-2025)
2 Global Hyperphosphatemia Drugs Market Competition by Manufacturers
- 2.1 Global Hyperphosphatemia Drugs Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Hyperphosphatemia Drugs Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Hyperphosphatemia Drugs Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Hyperphosphatemia Drugs Production Sites, Area Served, Product Types
- 2.5 Hyperphosphatemia Drugs Market Competitive Situation and Trends
- 2.5.1 Hyperphosphatemia Drugs Market Concentration Rate
- 2.5.2 Hyperphosphatemia Drugs Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Hyperphosphatemia Drugs Production Market Share by Regions
- 3.1 Global Hyperphosphatemia Drugs Production Market Share by Regions
- 3.2 Global Hyperphosphatemia Drugs Revenue Market Share by Regions (2014-2019)
- 3.3 Global Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Hyperphosphatemia Drugs Production
- 3.4.1 North America Hyperphosphatemia Drugs Production Growth Rate (2014-2019)
- 3.4.2 North America Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Hyperphosphatemia Drugs Production
- 3.5.1 Europe Hyperphosphatemia Drugs Production Growth Rate (2014-2019)
- 3.5.2 Europe Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Hyperphosphatemia Drugs Production (2014-2019)
- 3.6.1 China Hyperphosphatemia Drugs Production Growth Rate (2014-2019)
- 3.6.2 China Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Hyperphosphatemia Drugs Production (2014-2019)
- 3.7.1 Japan Hyperphosphatemia Drugs Production Growth Rate (2014-2019)
- 3.7.2 Japan Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Hyperphosphatemia Drugs Consumption by Regions
- 4.1 Global Hyperphosphatemia Drugs Consumption by Regions
- 4.2 North America Hyperphosphatemia Drugs Consumption (2014-2019)
- 4.3 Europe Hyperphosphatemia Drugs Consumption (2014-2019)
- 4.4 China Hyperphosphatemia Drugs Consumption (2014-2019)
- 4.5 Japan Hyperphosphatemia Drugs Consumption (2014-2019)
5 Global Hyperphosphatemia Drugs Production, Revenue, Price Trend by Type
- 5.1 Global Hyperphosphatemia Drugs Production Market Share by Type (2014-2019)
- 5.2 Global Hyperphosphatemia Drugs Revenue Market Share by Type (2014-2019)
- 5.3 Global Hyperphosphatemia Drugs Price by Type (2014-2019)
- 5.4 Global Hyperphosphatemia Drugs Production Growth by Type (2014-2019)
6 Global Hyperphosphatemia Drugs Market Analysis by Applications
- 6.1 Global Hyperphosphatemia Drugs Consumption Market Share by Application (2014-2019)
- 6.2 Global Hyperphosphatemia Drugs Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Hyperphosphatemia Drugs Business
- 7.1 Keryx Biopharmaceuticals
- 7.1.1 Keryx Biopharmaceuticals Hyperphosphatemia Drugs Production Sites and Area Served
- 7.1.2 Hyperphosphatemia Drugs Product Introduction, Application and Specification
- 7.1.3 Keryx Biopharmaceuticals Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Sanofi
- 7.2.1 Sanofi Hyperphosphatemia Drugs Production Sites and Area Served
- 7.2.2 Hyperphosphatemia Drugs Product Introduction, Application and Specification
- 7.2.3 Sanofi Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Shire
- 7.3.1 Shire Hyperphosphatemia Drugs Production Sites and Area Served
- 7.3.2 Hyperphosphatemia Drugs Product Introduction, Application and Specification
- 7.3.3 Shire Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Vifor Pharma
- 7.4.1 Vifor Pharma Hyperphosphatemia Drugs Production Sites and Area Served
- 7.4.2 Hyperphosphatemia Drugs Product Introduction, Application and Specification
- 7.4.3 Vifor Pharma Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Amgen
- 7.5.1 Amgen Hyperphosphatemia Drugs Production Sites and Area Served
- 7.5.2 Hyperphosphatemia Drugs Product Introduction, Application and Specification
- 7.5.3 Amgen Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 Bayer
- 7.6.1 Bayer Hyperphosphatemia Drugs Production Sites and Area Served
- 7.6.2 Hyperphosphatemia Drugs Product Introduction, Application and Specification
- 7.6.3 Bayer Hyperphosphatemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
8 Hyperphosphatemia Drugs Manufacturing Cost Analysis
- 8.1 Hyperphosphatemia Drugs Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Hyperphosphatemia Drugs
- 8.4 Hyperphosphatemia Drugs Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Hyperphosphatemia Drugs Distributors List
- 9.3 Hyperphosphatemia Drugs Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Hyperphosphatemia Drugs Market Forecast
- 11.1 Global Hyperphosphatemia Drugs Production, Revenue Forecast
- 11.1.1 Global Hyperphosphatemia Drugs Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Hyperphosphatemia Drugs Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Hyperphosphatemia Drugs Price and Trend Forecast (2019-2025)
- 11.2 Global Hyperphosphatemia Drugs Production Forecast by Regions (2019-2025)
- 11.2.1 North America Hyperphosphatemia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Hyperphosphatemia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.3 China Hyperphosphatemia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Hyperphosphatemia Drugs Production, Revenue Forecast (2019-2025)
- 11.3 Global Hyperphosphatemia Drugs Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Hyperphosphatemia Drugs Consumption Forecast (2019-2025)
- 11.3.2 Europe Hyperphosphatemia Drugs Consumption Forecast (2019-2025)
- 11.3.3 China Hyperphosphatemia Drugs Consumption Forecast (2019-2025)
- 11.3.4 Japan Hyperphosphatemia Drugs Consumption Forecast (2019-2025)
- 11.4 Global Hyperphosphatemia Drugs Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Hyperphosphatemia Drugs Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Hyperphosphatemia Drugs. Industry analysis & Market Report on Hyperphosphatemia Drugs is a syndicated market report, published as Global Hyperphosphatemia Drugs Market Research Report 2019. It is complete Research Study and Industry Analysis of Hyperphosphatemia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
